JWJue Wang

Jue Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jue Wang has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Super Mario Soldiers

    by Jue Wang

    The familiar, cheerful soundtrack of Super Mario drifted into the hallway, weaving its way through the usual sounds of the clinic.

  • Open Access

    Divergent Responses to Enfortumab Vedotin and Pembrolizumab in Concurrent Urothelial and Renal Cell Carcinoma: Case Report and Literature Review

    by Zane N. Gray, Qi Cai, Richard W. Ahn, Yair Lotan, Jue Wang

    Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has revolutionized the treatment of metastatic urothelial carcinoma (UC) and renal cell carcinoma (RCC). However, these cancers may exhibit divergent responses to the same immunotherapy. Here, we report a case of a patient with concurrent stage IV urothelial carcinoma (UC) and resected stage III clear cell renal cell carcinoma (ccRCC) of the contralateral kidney who experienced complete remission of UC following treatment with enfortumab vedotin (EV) and pembrolizumab but developed hyperprogression of metastatic RCC. As a result, the decision was made to discontinue ICIs and initiate a combination therapy of Lenvatinib (VEGF receptor inhibitor) and Everolimus (mTOR inhibitor). The patient exhibited a near complete radiographic response of the RCC to this combination therapy, with no significant side effects, and has remained well with minimal residual lung disease 18 months after the onset of hyperprogression in ccRCC. This highlights the role of distinct immune microenvironments in mediating differential responses to immunotherapy in patients with coexisting UC and ccRCC. We underscore the importance of personalized treatment strategies in patients with dual malignancies, particularly when divergent responses to immunotherapy are observed, offering durable responses while avoiding the risks associated with continued immune checkpoint inhibition.

  • Open Access

    Diagnostic utility of Ki-67 proliferation index, PSA, and other immunohistochemical markers in prostatic basal cell carcinoma: A review of 24 cases in the current literature and discussion on current treatment and diagnostics

    by Lister DeBinya, Vivek Mathesh, Jue Wang

    Background: Basal cell carcinoma (BCC) of the prostate is a rare and poorly characterized malignancy distinct from conventional prostatic adenocarcinoma. Due to its rarity, diagnostic challenges arise, often leading to misclassification and delayed management. Immunohistochemical markers such as Ki-67 proliferation index and prostate-specific antigen (PSA) levels may aid in distinguishing BCC from typical adenocarcinoma, but data remain limited. Methods: This case series review study retrospectively analyzes published case reports and series spanning from 1988 to 2023 to evaluate Ki-67 staining patterns, PSA levels, and other immunohistochemical features to identify distinguishing characteristics of prostatic BCC. Data extracted included patient demographics, PSA levels at presentation, Ki-67 proliferation index values, and results of other immunohistochemical staining (i.e., PSA, P63). Results: Of the 24 BCC cases included in the final analysis, 20 reported PSA level at first presentation (mean: 2.56 ng/mL, range 0.08-7.3 ng/mL, normal range <4), 15 reported PSA IHC staining, and only 13 reported Ki-67 percentage values obtained through primary tumor biopsy staining (mean: 46.88%, range 0-80%). In comparison, Ki-67 expression numbers from National Comprehensive Cancer Network (NCCN) for prostate adenocarcinoma report varied Ki-67 expressions between risk groups: low-risk patients averaged 5.1% ± 3.8%, intermediate-risk patients averaged 7.4% ± 6.8%, and high-risk patients averaged 12.0% ± 12.4%. Various immunohistochemical staining was also collected yielding positive staining with Ki-67 in 13/13 cases, HMWCK/34βE12 in 14/14 cases, P63 in 14/14 cases, and BCL-2 in 12/13 cases. Conclusion: This retrospective analysis suggests that prostatic BCC may be characterized by higher Ki-67 proliferation indices and lower PSA levels compared to typical prostatic adenocarcinoma. This review further explores and proposes the potential of combining Ki-67 and PSA assessments along with other biomarkers to aid in distinguishing BCC from conventional prostate cancers, facilitating earlier recognition and appropriate management of this rare malignancy.

  • Open Access

    Diagnosis and Management of Sarcoidosis-like Reaction in Adjuvant Immunotherapy: A Comprehensive Review and Clinical Implications

    by Matthew Lee, Qi Cai, Jue Wang

    Immune checkpoint inhibitors (ICIs) have transformed oncologic care and are increasingly used as adjuvant therapy to reduce the risk of recurrence. However, this shift has introduced immune-related adverse events (irAEs) to patients who may otherwise be clinically disease-free after definitive therapy. Sarcoidosis-like reaction (SLR) is an uncommon but important irAE characterized by non-necrotizing granulomatous inflammation. In the adjuvant setting, SLR is uniquely consequential because it can closely mimic recurrent malignancy on surveillance imaging and thereby prompt unnecessary diagnostic procedures, treatment interruption, or escalation of care. This review summarizes the current evidence on ICI-associated SLR with an emphasis on adjuvant immunotherapy, where practical guidance remains limited. We integrate evidence from clinical trials, real-world cohorts, and published case series to summarize the reported incidence of SLR, proposed immunologic mechanisms, clinical and radiographic presentation, pathology, differential diagnosis, and management. Particular attention is given to the problem of distinguishing SLR from recurrence, when tissue confirmation should be prioritized, and how management should be individualized according to clinical severity and organ involvement. Common radiographic features include bilateral mediastinal and hilar lymphadenopathy and pulmonary nodules, but tissue confirmation remains the diagnostic gold standard when feasible. Many cases are low grade and may be managed conservatively. Greater recognition of ICI-associated SLR is critical to avoid misdiagnosis and unnecessary escalation of care while preserving the therapeutic benefit of adjuvant immunotherapy.


  • Open Access

    Non-small Cell Lung Cancer in Metastatic Renal Cell Carcinoma Patients

    by Jake N. Lichterman, Matthew Lee, Alana Christie, Fernando Kay, Payal Kapur, James Brugarolas, Jue Wang

  • Open Access

    Novel Combination of Metronomic Cyclophosphamide and Darolutamide Induces Sustained Clinical Response in Heavily Treated Prostate Cancer with Prostate-Specific Membrane Antigen-Negative Liver Metastases and Rapid Disease Progression

    by Viral M. Patel, Qi Cai, Richard Ahn, Katherine Hill, Jue Wang

    Introduction: Treatment options for refractory prostate-specific membrane antigen (PSMA)-negative liver metastases from metastatic castration-resistant prostate cancer (mCRPC) are limited and challenging. This case report presents our clinical observation of a sustained response to a novel combination of metronomic cyclophosphamide (mCyc) and darolutamide in a 65-year-old male with heavily treated PSMA-negative mCRPC with rapid disease progression. Case Presentation: The patient was initially diagnosed 4 years prior to our evaluation with metastatic prostate cancer and treated with androgen deprivation therapy with leuprolide, enzalutamide, and definitive external beam radiation therapy to the prostate and pelvic lymphadenopathy, along with stereotactic body radiation to oligometastatic bone disease. Upon progression to mCRPC, he received abiraterone with prednisone followed by docetaxel with prednisone, both of which resulted in temporary disease stabilization but eventual rapid progression with deterioration in performance status. Given the lack of effective, tolerable options, a combination of mCyc and darolutamide was initiated. The patient demonstrated an impressive clinical response, including significant radiographic response in liver metastatic disease, an 80% reduction in prostate-specific antigen levels, and improved quality of life with resolution of all cancer-related symptoms without significant treatment-related toxicities, with ongoing response. Conclusion: This report highlights the complex challenges of managing mCRPC with PSMA-negative liver metastases. mCyc with darolutamide may represent a valuable therapeutic option for elderly patients with multiple comorbidities who have exhausted standard treatment options. However, further research is needed to establish the efficacy and safety of this combination in broader populations.


  • Open Access

    Radiation‐Associated Aortocolonic Fistula in Urothelial Carcinoma: Multidisciplinary Management and Case Report

    by Matthew Lee, Anil K. Pillai, Christopher Fan, Qi Cai, Kristi Baker, Jue Wang

    Upper tract urothelial carcinoma (UTUC) is an uncommon and aggressive malignancy that often presents as an invasive disease. After receiving systemic therapy, stereotactic body radiation therapy (SBRT) offers a non‐surgical option for consolidative local tumor control by delivering radiation doses in limited fractions. While SBRT is generally well tolerated in the treatment of UTUC, there is a small but serious risk of radiation‐associated complications. We present a case of a 67‐year‐old male with metastatic UTUC of the renal pelvis treated with chemotherapy and immunotherapy. Due to persistent disease at the primary site, he underwent consolidative SBRT using a PULSAR (Personalized Ultra‐fractionated Stereotactic Adaptive Radiotherapy) approach to his left kidney mass. Weeks later, he developed a renocolic fistula that was complicated by sepsis. Despite a diverting colostomy and antibiotics, he re‐presented with hemorrhagic shock due to an aortocolonic fistula that required emergent endovascular aortic repair (EVAR). This case illustrates a rare but serious complication of consolidative SBRT in a patient with extensive retroperitoneal malignancy. Multidisciplinary planning and close surveillance are critical to ensuring the safe integration of SBRT in the management of metastatic UTUC.

  • Open Access

    Concurrent Renal Cell Carcinoma Diagnosis in a Married Couple: Risk Factors and Unmet Survivorship Needs

    by Matthew Lee, Liwei Jia, Richard Ahn, Jue Wang

    Renal cell carcinoma (RCC) is the most common type of kidney cancer, but it is exceedingly rare for both partners in a married couple to be diagnosed with RCC within a short time frame. This case report describes a married couple who were diagnosed with RCC in close succession, exploring potential risk factors and highlighting the unmet survivorship needs of couples affected by cancer. Both partners shared risk factors, including a history of smoking and hypertension. The case focuses on the role of shared environmental exposures, specifically the wife’s occupation as a house cleaner and the husband’s role as a floor installer, in potentially contributing to carcinogenic risks in occupational settings. However, no hereditary RCC syndromes were identified. This report emphasizes the need for integrated care models that address the unique challenges faced by couples with concurrent cancer diagnoses, ensuring comprehensive support for both patients and their caregivers.

  • Open Access

    Managing elderly patients with dual metastatic cancers—navigating diagnostic and treatment challenges

    by Zane Gray, Nicholas Levonyak, Liwei Jia, Richard Ahn, Jyoti Balani, Jue Wang

    Prostate and colorectal adenocarcinoma are among the most common primary cancer diagnoses in the United States, with 29% of new cancer diagnoses among adult men in 2024 expected to arise from the prostate and another 15% across men and women being colorectal in origin. Given therapeutic advancements leading to improved survival, individuals with prostate cancer have the highest estimated probability of concurrent secondary primary malignancy. This represents a clinical dilemma as the treatment for each is distinct and impacted by histology, stage, and molecular findings. Herein, we describe a patient with significant comorbidities, found to have simultaneous metastatic prostate and colorectal adenocarcinomas, who achieved sustained complete remission of liver and lung metastases with a chemohormonal regimen.

  • Open Access

    New Mediastinal and Hilar Lymphadenopathy After Adjuvant Pembrolizumab in a Patient With Stage III Clear Cell Renal Cell Carcinoma

    by Matthew Lee, Kim Styrvoky, Qi Cai, Phillip Taboada, Remington Hoyer, Zane Gray, Nicholas Levonyak, Luis De Las Casas, Jue Wang

    The advent of immune checkpoint inhibitors (ICIs) has transformed the management of advanced and high-risk renal cell carcinoma (RCC). In the adjuvant setting, ICIs, such as pembrolizumab, aim to reduce the risk of recurrence following potentially curative nephrectomy. However, this therapeutic approach introduces unique challenges, particularly related to immune-related adverse events (irAEs). The sarcoidosis-like reaction is a particularly rare immune-related adverse event that can be a diagnostic challenge because of its broad clinical symptoms and potential to mimic metastasis. We present a case of a 50-year-old patient who developed mediastinal and hilar lymphadenopathy during adjuvant pembrolizumab therapy following nephrectomy for stage III RCC, which was initially suspected to be metastatic renal cell carcinoma. Endobronchial ultrasound (EBUS) biopsy revealed non-caseating granulomas without malignancy, leading to a diagnosis of pembrolizumab-induced sarcoidosis-like reaction (SLR). The patient was treated with corticosteroids due to progressive fatigue, leading to a complete resolution of his constitutive symptoms and mediastinal lymphadenopathy. This study highlights diagnostic and therapeutic challenges, the importance of distinguishing irAEs from cancer progression, and strategies to avoid cognitive bias in clinical decision making.